|
1
|
Ministry of Health, Labour and Welfare:
The Dynamic Statistics of the Population in 2014 (In Japanese).
http://www.mmjp.or.jp/kawakami-clinic/data/h26gan.htmAccessed.
November 1–2015.
|
|
2
|
Ishii H, Furuse J, Boku N, Okusaka T,
Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K and Fukuda H:
JCOG Gastrointestinal Oncology Study Group: Phase II study of
gemcitabine chemotherapy alone for locally advanced pancreatic
carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagner M, Redaelli C, Lietz M, Seiler CA,
Friess H and Bücher MW: Curative resection is the single most
important factor determining outcome in patients with pancreatic
adenocarcinoma. Br J Surg. 91:586–594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verbeke CS and Menon KV: Redefining
resection margin status in pancreatic cancer. HPB (Oxford).
11:282–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esposito I, Kleeff J, Bergmann F, Reiser
C, Herpel E, Friess H, Schirmacher P and Büchler MW: Most
pancreatic cancer resections are R1 resections. Ann Surg Oncol.
15:1651–1660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagakawa T, Kurachi M, Konishi K and
Miyazaki I: Translateral retroperitoneal approach in radical
surgery for pancreatic carcinoma. Jpn J Surg. 12:229–233. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagakawa T, Nagamori M, Futakami F,
Tsukioka Y, Kayahara M, Ohta T, Ueno K and Miyazaki I: Result of
extensive surgery for pancreatic carcinoma. Cancer. 77:640–645.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kitagawa H, Tajima H, Nakagawara H, Makino
I, Miyashita T, Shoji M, Nakanuma S, Hayashi N, Takamura H, Ohta T
and Ohtake H: En bloc vascular resection for the treatment of
borderline resectable pancreatic head carcinoma. Mol Clin Oncol.
2:369–374. 2014.PubMed/NCBI
|
|
9
|
Hirano S, Kondo S, Hara T, Ambo Y, Tanaka
E, Shichinohe T, Suzuki O and Hazama K: Distal pancreatectomy with
en bloc celiac axis resection for locally advanced pancreatic body
cancer: Long-term results. Ann Surg. 246:46–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kitagawa H, Tajima H, Nakagawara H, Makino
I, Miyashita T, Terakawa H, Nakanuma S, Hayashi H, Takamura H and
Ohta T: A modification of radical antegrade modular
pancreatosplenectomy for adenocarcinoma of the left pancreas:
Significance of en bloc resection including the anterior renal
fascia. World J Surg. 38:2448–2454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nimura Y, Nagino M, Takao S, Takada T,
Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda
Y, et al: Standard versus extended lymphadenectomy in radical
pancreatoduodenectomy for ductal adenocarcinoma of the head of the
pancreas: Long-term results of a Japanese multicenter randomized
controlled trial. J Hepatobiliary Pancreat Sci. 19:230–241. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreasDe Vita Hellman S and Rosenberg SA: Cancer:
Principles and practice of oncology. 6th. Philadelphia: Lippincott,
Williams and Wilkins; pp. 1126–1161. 2001
|
|
13
|
Kalser MH and Ellenberg SS: Pancreatic
cancer. Adjuvant combined radiation and chemotherapy following
curative resection. Arch Surg. 120:899–903. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bakkevold KE, Arnesjø B, Dahl O and
Kambestad B: Adjuvant combination chemotherapy (AMF) following
radical resection of carcinoma of the pancreas and papilla of
Vater-results of a controlled, prospective, randomised multicentre
study. Eur J Cancer. 29A:698–703. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lygidakis NJ and Stringaris K: Adjuvant
therapy following pancreatic resection for pancreatic duct
carcinoma: A prospective randomized study. Hepatogastroenterology.
43:671–680. 1996.PubMed/NCBI
|
|
16
|
Klinkenbijl JH, Jeekel J, Sahmoud T, van
Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT,
Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil
after curative resection of cancer of the pancreas and
periampullary region: Phase III trial of the EORTC gastrointestinal
tract cancer cooperative group. Ann Surg. 230:776–784. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lygidakis NJ, Sgourakis G, Georgia D,
Vlachos L and Raptis S: Regional targeting chemoimmunotherapy in
patients undergoing pancreatic resection in an advanced stage of
their disease: A prospective randomized study. Ann Surg.
236:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukutomi A, Uesaka K, Boku N, Kanemoto H,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: JASPAC 01: Randomized phase III trial of adjuvant
chemotherapy with gemcitabine versus S-1 for patients with resected
pancreatic cancer. J Clin Oncol. 31:(Suppl): abstr 4008.
2013.PubMed/NCBI
|
|
21
|
Spitz FR, Abbruzzese JL, Lee JE, Pisters
PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA
and Evans DB: Preoperative and postoperative chemoradiation
strategies in patients treated with pancreaticoduodenectomy for
adenocarcinoma of the pancreas. J Clin Oncol. 15:928–937. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yeo CJ, Abrams RA, Grochow LB, Sohn TA,
Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, et
al: Pancreaticoduodenectomy for pancreatic adenocarcinoma:
Postoperative adjuvant chemoradiation improves survival. A
prospective, single-institution experience. Ann Surg. 225:621–636.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tajima H, Ohta T, Kitagawa H, Okamoto K,
Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H,
et al: Pilot study of neoadjuvant chemotherapy with gemcitabine and
oral S-1 for resectable pancreatic cancer. Exp Therap Med.
3:787–792. 2012.
|
|
24
|
Vauthey JN and Dixon E: AHPBA/SSO/SSAT
consensus conference on resectable and borderline resectable
pancreatic cancer: Rationale and overview of the conference. Ann
Surg Oncol. 16:1725–1726. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zakharova OP, Karmazanovsky GG and Egorov
VI: Pancreatic adenocarcinoma: Outstanding problems. World J
Gastrointest Surg. 4:104–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Varadhachary GR, Tamm EP, Abbruzzese JL,
Xingo HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff
RA: Borderline resectable pancreatic cancer: Definitions,
management, and role of preoperative therapy. Ann Surg Oncol.
13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moore GE, Sako Y and Thoms LB: Radical
pancreatoduodenectomy with resection and reanastomosis of the
superior mesenteric vein. Surgery. 30:550–553. 1951.PubMed/NCBI
|
|
28
|
Siriwardana HP and Siriwardena AK:
Systematic review of outcome of synchronous portal-superior
mesenteric vein resection during pancreatectomy for cancer. Br J
Surg. 93:662–673. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Glanemann M, Shi B, Liang F, Sun XG, Bahra
M, Jacob D, Neumann U and Neuhaus P: Surgical strategies for
treatment of malignant pancreatic tumors: Extended, standard of
local surgery? World J Surg Oncol. 6:1232008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Polistina F, Di Natale G, Bonciarelli G,
Ambfosino G and Frego M: Neoadjuvant strategies for pancreatic
cancer. World J Gastroenterol. 20:9374–9383. 2014.PubMed/NCBI
|
|
31
|
Lim KH, Chung E, Khan A, Cao D, Linehan D,
Ben-Josef E and Wang-Gilliam A: Neoadjuvant therapy of pancreatic
cancer: The emerging paradigm? Oncologist. 17:192–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Assifi MM, Lu X, Eibl G, Reber HA, Li G
and Hines OJ: Neoadjuvant therapy in pancreatic adenocarcinoma: A
meta-analysis of phase II trials. Surgery. 150:466–473. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Satoi S, Yanagimoto H, Toyokawa H,
Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S
and Kwon AH: Surgical results after preoperative chemoradiation
therapy for patients with pancreatic cancer. Pancreas. 38:282–288.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hosein PJ, Macintyre J, Kawamura C,
Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A,
Portelance L, Merchan JR, et al: A retrospective study of
neoadjuvant FOLFIRINOX in unresectable of borderline resectable
locally advanced pancreatic adenocarcinoma. BMC Cancer. 12:1992012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Postoperative/neoadjuvant
therapy in pancreatic cancer: A systemic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chandler NM, Cante JJ, Stuart KE and
Callery MP: Preoperative chemoradiation in resectable pancreatic
cancer. J Hepatobiliary Pancreat Surg. 10:61–66. 2003.PubMed/NCBI
|
|
37
|
Evans DB: Preoperative chemoradiation for
resectable and locally advanced adenocarcinoma of the pancreas. J
Gastrointest Surg. 5:2–5. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Russo S, Chabot J and Saif MW: Resectable
pancreatic cancer: Is surgery the best first step? JOP. 13:151–154.
2012.PubMed/NCBI
|
|
39
|
Abbot DE, Tzeng CW, Merkow RP, Cantor SB,
Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary
GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is
superior to a surgery-first approach in the treatment of pancreatic
head adenocarcinoma. Ann Surg Oncol. 20:(Suppl 3). S500–S508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et
al: Gemcitabine in combination with oxaliplatin compared with
gemcitabine alone in locally advanced or metastatic pancreatic
cancer: Results of a GERCOR and GISCAD phase III trial. J Clin
Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kindler HI, Niedzwiecki D, Hollis D,
Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF,
O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab
compared with gemcitabine plus placebo in patients with advanced
pancreatic cancer: Phase III trial of the Cancer and Leukemia Group
B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Andriulli A, Festa V, Botteri E, Valvno
MR, Koch M, Bassi C, Maisonneuve P and Sebastiano PD:
Neoadjuvant/preoperative gemcitabine for patients with localized
pancreatic cancer: A meta-analysis of prospective studies. Ann Surg
Oncol. 19:1644–1662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee JL, Kim SC, Kim JH, Lee SS, Kim TW,
Park DH, Seo DW, Lee SK, Kim MH, Kim JH, et al: Prospective
efficacy and safety study of neoadjuvant gemcitabine with
capecitabine combination chemotherapy for borderline-resectable or
unresectable locally advanced pancreatic adenocarcinoma. Surgery.
152:851–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sahora K, Kuehrer I, Schindl M,
Koelblinger C, Goetzinger P and Gnant M: NeoGemTax: Gemcitabine and
docetaxel as neoadjuvant treatment for locally advanced
nonmetastasized pancreatic cancer. World J Surg. 35:1580–1589.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Eng J Med. 364:1817–1825. 2011.
View Article : Google Scholar
|
|
46
|
Christians KK, Tsai S, Mahmoud A, Ritch P,
Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB and
George B: Neoadjuvant FOLFIRINOX for borderline resectable pancreas
cancer: A new treatment paradigm? Oncologist. 19:266–274. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Paniccia A, Edil BH, Schulick RD, Byers
JT, Meguid C, Gajdos C and McCarter MD: Neoadjuvant FOLFIRINOX
application in borderline resectable pancreatic adenocarcinoma: A
retrospective Cohort study. Med. 93:e1982014. View Article : Google Scholar
|
|
48
|
Blazer M, Wu C, Goldberg RM, Phillips G,
Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J,
Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally
advanced unresectable (LAPC) and borderline resectable (BRPC)
adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ferrone CR, Marchegiani G, Hong TS, Ryan
DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN,
Blaszkowsky LS, et al: Radiological and surgical implications of
neoadjuvant treatment with FOLFIRINOX for locally advanced and
borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Alvarez R, Musteanu M, Garcia-Garcia E,
Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A,
Rodriguez-Pascual J, et al: Stromal disrupting effects of
nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chiorean EG and Von Hoff DD: Taxanes:
Impact on pancreatic cancer. Anticancer Drugs. 25:584–592. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shinchi H, Takao S, Noma H, Matsuo Y,
Mataki Y, Mori S and Aikou T: Length and quality of survival after
external-beam radiotherapy with concurrent continuous
5-fluorouracil infusion for locally unresectable pancreatic cancer.
Int J Radiat Oncol Biol Phys. 53:146–150. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Van Laethem JL, Hammel P, Mornex F, Azria
D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer
M, et al: Adjuvant gemcitabine alone versus gemcitabine-based
chemoradiotherapy after curative resection for pancreatic cancer: A
Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. J
Clin Oncol. 28:4450–4456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Heinrich S, Pestalozzi BC, Schäfer M,
Weber A, Bauerfeind P, Knuth A and Clavien PA: Prospective phase II
trial of neoadjuvant chemotherapy with gemcitabine and cisplatin
for resectable adenocarcinoma of the pancreatic head. J Clin Oncol.
26:2526–2531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Heinrich S, Pestalozzi B, Lesurtel M,
Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour
P, Moehler M, et al: Adjuvant gemcitabine versus NEOadjuvant
gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable
pancreatic cancer: A randomized multicenter phase III study (NEOPAC
study). BMC Cancer. 11:3462011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sho M, Akahori T, Tanaka T, Kinoshita S,
Tamamoto T, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, et
al: Pathological and clinical impact of neoadjuvant
chemoradiotherapy using full-dose gemcitabine and concurrent
radiation for resectable pancreatic cancer. J Hepatobiliary
Pancreat Sci. 20:197–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Van Buren G II, Ramanathan RK, Krasinskas
AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM,
Bartlett DL, et al: Phase II study of induction fixed-dose rate
gemcitabine and bevacizumab followed by 30 Gy radiotherapy as
preoperative treatment for potentially resectable pancreatic
adenocarcinoma. Ann Surg Oncol. 20:3787–3793. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mahadevan D and Von Hoff DD: Tumor-stroma
interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther.
6:1186–1197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Okamoto K, Tajima H, Ohta T, Nakanuma S,
Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa
H, et al: Angiotensin II induces tumor progression and fibrosis in
intrahepatic cholangiocarcinoma through an interaction with hepatic
stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Galván JA, Zlobec I, Wartenberg M, Lugli
A, Gloor B, Perren A and Karamitopoulou E: Expression of E-cadherin
repressors SNAIL, ZEB1 and ZEB2 by tumor and stromal cells
influences tumor-budding phenotype and suggests heterogeneity of
stromal cells in pancreatic cancer. Br J Cancer. 112:1944–1950.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Heeg S, Das KK, Reichert M, Bakir B,
Takano S, Caspers J, Aiello NM, Wu K, Neesse A, Maitra A, et al:
ETS-Transcription Factor TTV1 regurates stromal expansion and
metastasis in pancreatic cancer. Gastroenterology. 151:540–553.e14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Karnevi E, Rosendahl HA, Hilmersson SK,
Saleem AM and Andersson R: Impact by pancreatic stellate cells on
epithelial-mesenchymal transition and pancreatic cancer cell
invasion: Adding a third dimension in vitro. Exp Cell Res.
346:206–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Goses MJ, Dressen RC, Rutten HJ,
Nieuwenhuijzen GA, van der Laak JA, Martijn H, Tan-Go I, Nagtegaal
ID, van den Brule AJ and van Krieken JH: Preoperative
radiochemotherapy is successful also in patients with locally
advanced rectal cancer who have intrinsically high apoptotic
tumors. Ann Oncol. 19:2026–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tsukamoto H, Shibata K, Kajiyama H,
Terauchi M, Nawa A and Kikkawa F: Irradiation-induced
epithelial-mesenchymal transition (EMT) related to invasive
potential in endometrial carcinoma cells. Gynecol Oncol.
107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tajima H, Ohta T, Makino I, Hayashi H,
Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa H, et al:
Expression of epithelial-mesenchymal transition markers in locally
recurrent hepatocellular carcinoma after radiofrequency ablation.
Exp Therap Med. 1:347–350. 2010. View Article : Google Scholar
|
|
70
|
Tajima H, Ohta T, Kitagawa H, Okamoto K,
Sakai S, Kinoshita J, Makino I, Furukawa H, Hayashi H, Nakamura K,
et al: Neoadjuvant chemotherapy with gemcitabine for pancreatic
cancer increases in situ expression of the apoptosis marker M30 and
stem cell marker CD44. Oncol Let. 3:1186–1190. 2011.
|
|
71
|
Zhang D, Sun L, Xian W, Liu F, Ling G,
Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel
ameliorates renal fibrosis in rat UUO model by inhibition of
TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhou J, Zhong DW, Wang QW, Miao XY and Xu
XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via
inhibition of TGF-beta/Smad activity. World J Gastroenterol.
16:3330–3334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Choi HS, Savard CE, Choi JW, Kuver R and
Lee SP: Paclitaxel interrupts TGF-beta1 signaling between
gallbladder epithelial cells and myofibroblasts. J Surg Res.
141:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–1920. 2013.PubMed/NCBI
|
|
75
|
Cufí S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to- mesenchymal
transition (EMT): From cancer stem cells to aging-associated
fibrosis. Cell Cycle. 9:4461–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cell ontogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chang TI, Kang HY, Kim KS, Lee SH, Nam BY,
Paeng J, Kim S, Park JT, Yoo TH, Kang SW and Han SH: The effect of
statin on epithelial-mesenchymal transition in peritoneal
mesothelial cells. PLoS One. 9:e1096282014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yang T, Chen M and Sun T: Simvastatin
attenuates TGF-β1-induced epithelial-mesenchymal transition in
human alveolar epithelial cells. Cell Physiol Biochem. 31:863–874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shoji M, Ninomiya I, Makino I, Kinoshita
J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura
H, et al: Valproic acid, a histone deacetylase inhibitor, enhances
radiosensitivity in esophageal squamous cell carcinoma. Int J
Oncol. 40:2140–2146. 2012.PubMed/NCBI
|
|
82
|
Watanabe T, Tajima H, Hironori H,
Nakagawara H, Ohnishi I, Takamura H, Ninomiya I, Kitagawa H,
Fushida S, Tani T, et al: Sodium valproate blocks the transforming
growth factor (TGF)-β1 autocrine loop and attenuates the
TGF-β1-induced collagen synthesis in a human hepatic stellate cell
line. Int J Mol Med. 28:919–925. 2011.PubMed/NCBI
|
|
83
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11–20. 2011.PubMed/NCBI
|
|
84
|
Li D, Yeung SC, Hassan MM, Konopleva M and
Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic
cancer. Gastroenterology. 137:482–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Nakai Y, Isayama H, Ijichi H, Sasaki T,
Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y,
et al: Inhibition of renin-angiotensin system affects prognosis of
advanced pancreatic cancer receiving gemcitabine. Br J Cancer.
103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Sun JD, Liu Q, Ahluwalia D, Li W, Meng F,
Wang Y, Bhupathi D, Ruprell AS and Hart CP: Efficacy and safety of
the hypoxia-activated prodrug TH-302 in combination with
gemcitabine and nab-paclitaxel in human tumor xenograft models of
pancreatic cancer. Cancer Biol Ther. 16:438–449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang D, Yang R, Wang S and Dong Z:
Paclitaxel: New uses for an old drug. Drug Des Devel Ther.
8:279–284. 2014.PubMed/NCBI
|
|
88
|
Meng H, Wang M, Liu H, Liu X, Situ A, Wu
B, Ji Z, Chang CH and Nel AE: Use of a lipid-coated mesoporous
silica nanoparticle platform for synergistic gemcitabine and
paclitaxel delivery to human pancreatic cancer in mice. ACS Nano.
9:3540–3557. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Oettle H: Progress in the knowledge and
treatment of advanced pancreatic cancer: From benchside to bedside.
Cancer Treat Rev. 40:1039–1047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Iwahashi S, Utsunomiya T, Imura S, Morine
Y, Ikemoto T, Arakawa Y, Saito Y, Ishikawa D and Shimada M: Effects
of valproic acid in combination with S-1 on advanced
pancreatobiliary tract cancers: Clinical study phases I/II.
Anticancer Res. 34:5187–5191. 2014.PubMed/NCBI
|
|
91
|
Poste G and Greig R: On the genesis and
regulation of cellular heterogeneity in malignant tumors. Invasion
Metastasis. 2:137–176. 1982.PubMed/NCBI
|
|
92
|
Hindriksen S and Bijlsma MF: Cancer stem
cells, emt, and developmental pathway activat ion in pancreatic
tumors. Cancers (Basel). 4:989–1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Xu X, Rao GS, Groh V, Spies T, Gattuso P,
Kaufman HL, Plate J and Prinz RA: Major histocompatibility complex
class I-related chain A/B (MICA/B) expression in tumor tissue and
serum of pancreatic cancer: Role of uric acid accumulation in
gemcitabine-induced MICA/B expression. BMC Cancer. 11:1942011.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Miyashita T, Tajima H, Shoji M, Nakanuma
S, Sakai S, Makino I, Hayashi H, Nakagawara H, Takamura H, Kitagawa
H and Ohta T: Gemcitabine augments major histocompatibility complex
class I-related chain A expression in pancreatic cancer. Gan To
Kagaku Ryoho. 40:1600–1602. 2013.(In Japanese). PubMed/NCBI
|
|
96
|
Waldhauer I, Goehlsdorf D, Gieseke F,
Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG
and Steinle A: Tumor-associated MICA is shed by ADAM proteases.
Cancer Res. 68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ashiru O, Boutet P, Fernández-Messina L,
Agüera-González S, Skepper JN, Valés-Gómez M and Reyburn HT:
Natural killer cell cytotoxicity is suppressed by exposure to the
human NKG2D ligand MICA*008 that is shed by tumor cells in
exosomes. Cancer Res. 70:481–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chitadze G, Lettau M, Bhat J, Wesch D,
Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH
and Kabelitz D: Shedding of endogenous MHC class I-related chain
molecules A and B from different human tumor entities:
Heterogeneous involvement of the ‘a disintegrin and
metalloproteases’ 10 and 17. Int J Cancer. 133:1557–1566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Penafuerte C, Bautista-Lopez N,
Bouchentouf M, Birman E, Forner K and Galipeau J: Novel TGF-beta
antagonist inhibits tumor growth and angiogenesis by inducing IL-2
receptor-driven STAT1 activation. J Immunol. 186:6933–6944. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lu J, Shi J, Li M, Gui B, Fu R, Yao G,
Duan Z, Lv Z, Yang Y, Chen Z, et al: Activation of AMPK by
metformin inhibits TGF-β-induced collagen production in mouse renal
fibroblasts. Life Sci. 127:59–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Pscherer S, Freude T, Forst T, Nussler AK,
Braun KF and Ehnert S: Anti-diabetic treatment regulates
pro-fibrotic TGF-β serum levels in type 2 diabetics. Diabetol Metab
Syndr. 5:482013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Pühringer-Oppermann F, Sarbia M, Ott N and
Brücher BL: The predictive value of genes of the TGF-beta1 pathway
in multimodally treated squamous cell carcinoma of the esophagus.
Int J Colorectal Dis. 25:515–521. 2010. View Article : Google Scholar : PubMed/NCBI
|
